Biobankonomics: A taxonomy for evaluating the economic benefits of standardized centralized human biobanking for translational research

Journal of the National Cancer Institute - Monographs

Volumn , Issue 42, 2011, Pages 32-38

  Rogers, Joyce ^b   Carolin, Todd ^c   Vaught, Jimmie ^a   Compton, Carolyn ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

^b Kelly Services   (United States)

^c BOOZ ALLEN HAMILTON   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ARTICLE; CANCER RESEARCH; COST CONTROL; COST OF ILLNESS; ECONOMIC ASPECT; HEALTH CARE FACILITY; HUMAN; MEDICAL RESEARCH; PRIORITY JOURNAL; TAXONOMY; TRANSLATIONAL RESEARCH; BUDGET; COST BENEFIT ANALYSIS; ECONOMICS; METHODOLOGY; NEOPLASM; ORGANIZATION AND MANAGEMENT; STANDARD; STATISTICS;

BIOMEDICAL RESEARCH; BUDGETS; COST-BENEFIT ANALYSIS; HUMANS; NEOPLASMS; REFERENCE STANDARDS; TISSUE BANKS; TRANSLATIONAL RESEARCH;

EID: 80053417661     PISSN: 10526773     EISSN: 17456614     Source Type: Book Series    
DOI: 10.1093/jncimonographs/lgr010     Document Type: Article

References (22)

1. Daniel Stewart & Co. Equity Research Report on Asterand. 2008;2. Daniel Stewart & Co PLC, Healthcare Sector Analyst Reports, Asterand, March 30, 2010, p. 3., London.
2. Friede A, Grossman R, Hunt R, et al., eds. Biospecimen and data collection and distributionNational Biospecimen Network Blueprint [online].Durham, NC: Constella Group, Inc.; 2003. http://biospecimens.cancer.gov/practices/. Accessed June 23, 2010.
3. First-Generation Guidelines for NCI-Supported Biorepositories, Notice. Federal Register 2006;71(28):25184-25203. http://frwebgate2.access.gpo.gov/cgi-bin/TEXTgate.cgi?WAISdocID=p0OGqP/0/1/0&WAISaction=retrieve. Accessed November 2, 2010. http://frwebgate1.access.gpo.gov/cgi-bin/TEXTgate.cgi?WAISdocID=LrDmI1/25/1/0&WAISaction=retrieve.
4. Carande-Kuli VG, Getze TE, Thacker SB. Public goods and externalities: a research agenda for public health economics. J Public Health Manag Pract. 2007;13(2):227-232.
5. Bener J, Konig E. The growing role of biobanking in today's medical environment. BioProcess Int. 2010;8(3):10-14.
6. Ginsburg GS, Burke TW, Febbo P. Centralized biorepositories for genetic and genomic research. JAMA. 2008;299(11):1359-1361.
7. Carlson RJ. The disruptive nature of personalized medicine technologies: implications for the health care system. Public Health Genomics. 2009;12(3):180-184.
8. Ambs S, Marincola FM, Thurin M. Profiling of immune response to guide cancer diagnosis, prognosis, and prediction of therapy. Cancer Res. 2008;68(11):4031-4033.
9. Fee R. The cost of clinical trials. Drug Discovery and Development Magazine. 2007;10(3):32.
10. Khleif SN, Doroshow JH, Hait WN; AACR-FDA-NCI Cancer Biomarkers Collaborative. AACR-FDA-NCI Cancer Biomarkers Collaborative consensus report: advancing the use of biomarkers in cancer drug development. Clin Can Res. 2010;16(13):3299-3318.
11. Mariani SM. Conference report-Clinical pathology: The top 5 studies in the journal: highlights from the Annual Meeting of the American Society of Clinical Pathology. MedGenMed. 2003;5(4):18.
12. Reed SD, Anstrom KJ, Ludmer JA, Glendenning GA, Schulman KA. Cost-effectiveness of Imatinib versus interferon-a plus low-dose cytarabine for patients with newly diagnosed chronic-phase chronic myeloid leukemia. Cancer. 2004;101(11):2574-2583.
13. Kingsbury K. The value of a human life. Time Magazine, Health and Science. May 20, 2008. http://www.time.com/time/health/article/0,8599,1808049,00.html. Accessed November 1, 2010.
14. Witonsky J. Biorepository: Cornerstone of the Biomedical Research Organization. Health and Life Sciences Vital Signs. Frost & Sullivan; 2008.
15. National Cancer Institute. FactSheet, U.S. Cancer Research Annual Spending Statistics. http://www.cancer.gov/cancertopics/factsheet/NCI/research-funding. Accessed October 29, 2010.
16. Dauffenbach R, Larkin W. The Economic Significance of the Oklahoma Medical Research Foundation. An Economics Analysis prepared by the Center for Economic and Management Research. Oklahoma State University; 2006. http://omrf.org/wp-content/uploads/2010/03/EconomicDevelopment.pdf. Accessed November 2, 2010.
17. Aamodt R. National Biospecimen Network Blueprint [online]. Durham, NC: Constella Group, Inc.; 2003:91.
18. Andrews LB. Harnessing the benefits of biobanks. J Law Med Ethics. 2005;33(1):22-30.
19. http://herceptin.com/hcp/metastatic-treatment/studies-efficacy.jsp. Accessed November 2, 2010.
20. Herceptin proven to benefit women with HER2 positive early breast cancer, latest results from the HERA Study. Medical News Today. March 12, 2009. http://www.medicalnewstoday.com/articles/141959.php. Accessed October 29, 2010.
21. Davis JC, Furstenthal L, Desai AA, et al. The microeconomics of personalized medicine: today's challenge and tomorrow's promise. Nat Rev Drug Discov. 2009;8(4):279.
22. Postel V. My drug problem. The Atlantic. March 2009. http://www.theatlantic.com/magazine/archive/2009/03/my-drug-problem/7279/. Accessed October 29, 2010.